• For the latest updates on our ongoing response to COVID-19, please click here.

    Company Statements

    06/17/2020

    Gilead Sciences Statement on Phase 2/3 Clinical Trial of Remdesivir in Pediatric Patients Hospitalized With COVID-19

    06/01/2020

    Gilead Sciences Statement on Remdesivir Clinical Data

    05/29/2020

    Gilead Sciences Response to U.S. Senators on Trial Diversity

    05/22/2020

    Gilead Sciences Statement on NEJM Publication of Remdesivir Data From NIAID Study

    05/05/2020

    Gilead Sciences Statement on Expanding Global Supply of Investigational Antiviral Remdesivir

    04/24/2020

    Gilead Statement on Complaint Against Federal Government in The Court of Federal Claims

    04/23/2020

    Gilead Sciences Statement on Data From Remdesivir Study in Patients With Severe COVID-19 in China

    04/10/2020

    Gilead Sciences Response to Médecins Sans Frontières

    03/25/2020

    Gilead Sciences Statement on Request to Rescind Remdesivir Orphan Drug Designation

    03/23/2020

    Gilead Sciences Statement on Ensuring Continued  Supply of HIV Medicine Amid Coronavirus Outbreak

    03/22/2020

    Gilead Sciences Statement on Access to Remdesivir Outside of Clinical Trials

    02/05/2020

    Gilead Statement on U.S. Patent and Trademark Office Decision to Deny Request for Inter Partes Review of HIV PrEP Patents

    01/31/2020

    Gilead Sciences Statement on the Company’s Ongoing Response to the 2019 Novel Coronavirus (2019-nCoV)

    12/03/2019

    Gilead Statement on Commitment to Advancing Descovy for PrEP? Study in Cisgender Women & Adolescent Females

    11/07/2019

    Gilead Statement on U.S. Government Complaint Regarding HIV PrEP and PEP Patents

    08/21/2019

    Petitions to US Patent and Trademark Office on HIV PrEP Patents

    06/11/2019

    Gilead Sciences Statement on U.S. Preventive Services Task Force 'A' Recommendation for PrEP as an HIV Prevention Strategy

    05/14/2019

    Gilead Sciences Statement On Inaccurate Reporting On Truvada®

    04/10/2019

    Gilead Sciences Statement on Commitment to Providing Price Information

    04/04/2019

    Gilead Sciences Commits to Reducing our Global Greenhouse Gas Emissions by 25 Percent by 2025

    04/03/2019

    Gilead Sciences Announces $500,000 Grant To Pan American Development Foundation To Provide Emergency Health Services For Venezuelan Migrants And Host Communities In Colombia

    09/27/2018

    Gilead Sciences Statement on Grants to Spouses of Caricom Leaders Action Network (SCLAN) to Expand Access to Youth HIV Prevention and Care in the Caribbean

    09/24/2018

    A perspective from our CEO: Gilead Subsidiary to Launch Authorized Generics to Treat HCV

    09/07/2018

    Gilead Sciences Announces Steep Discounts for Ambisome to Treat Cryptococcal Meningitis in Low- and Middle-Income Countries

    05/02/2018

    Gilead Publishes 2017 Year in Review

    11/09/2017

    Gilead Sciences Announces 100 Percent Score on 2018 Human Rights Campaign Corporate Equality Index

    09/01/2017

    Gilead Implements Emergency Disaster Response Procedures to Ensure Medicine Access

    05/01/2017

    Gilead Publishes Year in Review 2016

    12/06/2016

    Gilead Recognized as Top Corporate Philanthropist in Funders Concerned About AIDS Report

    12/01/2016

    Gilead HIV Medicines Now Reaching 10 Million People in Developing Countries

    11/11/2016

    Statement on DISCOVER Study of F/TAF for PrEP

    08/01/2016

    Gilead Publishes 2015 Corporate Social Responsibility Report

    08/14/2015

    Gilead Supports PrEP Education to Increase HIV Prevention and Awareness

    08/12/2015

    Gilead Publishes Its 2014 Corporate Contributions Report

    Some of the content on this page is not intended for users outside the US.

    992tv在线香蕉